Credelio (lotilaner)

Credelio (lotilaner) is filed as Isoxazoline Parasiticide. The sections below restate public label fields stored for this profile.

Class
Isoxazoline Parasiticide
Generic name
lotilaner
Route
OPHTHALMIC
Dosage forms
3 DOSAGE FORMS AND STRENGTHS XDEMVY (lotilaner ophthalmic solution) is provided as an ophthalmic solution containing lotilaner 0.25% (2.5 mg/mL). Ophthalmic solution containing lotilaner 0.25%. ( 3 )
Manufacturer
Tarsus Pharmaceuticals, Inc.

Approved uses

1 INDICATIONS AND USAGE XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis. ( 1 )

How it works

12.1 Mechanism of Action Lotilaner is a gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor selective for mites. Inhibition of these GABA chloride channels causes a paralytic action in the target organism leading to its death. Lotilaner is not an inhibitor of mammalian GABA mediated chloride channels when tested at up to 30 µM (18 µg/mL) in vitro (approximately 1100 times the RHOD).

Contraindications

4 CONTRAINDICATIONS None. None. ( 4 )

Common side effects

As instillation site stinging and burning (10%)

Dosage and administration

2 DOSAGE AND ADMINISTRATION Instill one drop of XDEMVY in each eye twice daily (approximately 12 hours apart) for 6 weeks. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. If one dose is missed, treatment should continue with the next scheduled dose. Instill one drop of XDEMVY in each eye twice daily (approximately 12 hours apart) for 6 weeks. ( 2 )

Drug interactions

Limited structured drug interaction data is available from public sources for this veterinary product. Consult your veterinarian about potential interactions with other medications.

Common questions

What is Credelio approved to treat?

According to its FDA label, Credelio (lotilaner) is approved for: 1 INDICATIONS AND USAGE XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis. ( 1 ) For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Credelio?

Credelio (lotilaner) belongs to the Isoxazoline Parasiticide class of medications.

What form does Credelio come in?

The FDA label lists Credelio (lotilaner) as: 3 DOSAGE FORMS AND STRENGTHS XDEMVY (lotilaner ophthalmic solution) is provided as an ophthalmic solution containing lotilaner 0.25% (2.5 mg/mL). Ophthalmic solution containing lotilaner 0.25%. ( 3 ); ophthalmic route. Available strengths and packaging vary by manufacturer.

Does Credelio have a Boxed Warning?

Our ingest of the FDA label for Credelio (lotilaner) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Credelio cost?

Public CMS NADAC pricing for Credelio (lotilaner) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Credelio currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Credelio (lotilaner) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Credelio approved by the FDA?

The FDA record lists the approval date for Credelio (lotilaner) as 2023-07-24.

Who makes Credelio?

The FDA label lists Tarsus Pharmaceuticals, Inc. as a labeler/manufacturer of Credelio (lotilaner). Multiple firms may market generics of the same molecule.

How should Credelio be stored?

The FDA label states: "Storage Store at 15°C to 25°C (59°F to 77°F). After opening the XDEMVY bottle, it can be used until the expiration date on the bottle." Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…